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ABSTRACT 
Background and Aims 
The optimal duration of treatment with nucleos(t)ide analogues (NAs) for patients 
with HBeAg-negative Chronic Hepatitis B (CHB) is unknown. The aim of this study 
was to identify an immune signature associated with off-treatment remission to NA 
therapy.  
Methods 
We performed microarray analysis of PBMCs from six patients with chronic hepatitis 
B who stopped NA therapy (3 with off-treatment remission, 3 with relapse) and 5 
patients with chronic HBV infection (previously termed “inactive carriers”) served as 
controls. Results were validated using qRT-PCR on a second group of 21 individuals 
(17 patients who stopped treatment and 4 controls). PBMCs from 38 patients on 
long-term NA treatment were analysed for potential to stop treatment. 
Results 
Microarray analysis indicated that patients with off-treatment remission segregated 
as a distinct out-group. Twenty-one genes were selected for subsequent validation. 
Ten of these were expressed at significantly lower levels in the patients with off-
treatment remission compared to the patients with relapse and predicted remission 
with AUC of 0.78-0.92. IFNγ, IL-8, FASLG and CCL4 were the most significant by 
logistic regression. Twelve (31.6%) of 38 patients on long-term NA therapy had 
expression levels of all these four genes below cut-off values, and hence were 
candidates for stopping treatment. 
Conclusions 
Our data suggest that patients with HBeAg-negative CHB who remain in off-
treatment remission 3 years after NA cessation have a distinct immune signature and 
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that PBMC RNA levels of IFNγ, IL-8, FASLG and CCL4 may serve as potential 
biomarkers for stopping NA therapy. 
 
Keywords: Chronic hepatitis B; Nucleos(t)ide Analogues; treatment discontinuation 
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INTRODUCTION 
 
Chronic infection with hepatitis B virus (HBV) remains a serious public health 
problem worldwide with a high morbidity and mortality rate 1. Patients with active viral 
replication and necro-inflammation who remain untreated are at particular risk for 
cirrhosis and hepatocellular carcinoma (HCC) 2, 3. The infection can be controlled 
either with a limited course of interferon-α or long term nucleos(t)ide analogue (NA) 
therapy 4, 5. Potent first line nucleos(t)ide analogues (NAs) have been widely used 
and found to be associated with virological response, biochemical remission, 
reversion in liver fibrosis and significant reduction in morbidity and mortality 5-8. 
However, long-term administration of NAs has raised several safety and economic 
issues, making the question of treatment discontinuation an emerging issue 
especially in patients with HBeAg negative chronic hepatitis B (CHB). Several small 
studies have shown that a proportion of patients remained in remission after NA 
discontinuation 9-13. Therefore, the Asian Pacific Association 14 and more recently 
European guidelines 5 recommended that NAs could be discontinued in selected, 
non-cirrhotic HBeAg negative patients who have achieved virological suppression for 
at least 3 years and are under close monitoring 5. However, as 55% to 70% of 
patients relapse within 24 months after NA discontinuation, and since no acceptable 
end point marker exists to safely predict long term off treatment remission, NA 
discontinuation in HBeAg negative patients still remains a debatable issue 9-13.  
Control of HBV infection involves the host immune response to control viral 
replication, whilst HBV has evolved mechanisms to evade both innate and adaptive 
immune responses in order to establish persistent infection 15. Long-term therapy 
with NAs seems to facilitate the restoration of the host immune system following 
reduction of serum HBV DNA 16. Biochemical rebound in patients after NA 
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discontinuation, followed by HBsAg clearance in some of them, might be explained 
by the restoration of immune system functions at the time of NA discontinuation.  
Patients who can control virological rebound and remain in remission or develop off-
treatment HBsAg clearance may have different immunological characteristics 
compared to individuals in different stages of HBV infection. In this study we 
investigated whether peripheral blood mononuclear cell (PBMC) RNA levels are 
associated with off-therapy remission acting therefore as potential immune-related 
biomarkers to identify individuals with HBeAg-negative CHB on NA therapy who can 
benefit from stopping treatment.     
 
PATIENTS AND METHODS 
 
Patients  
In July 2013 we initiated a prospective multicentre study examining the potential of 
NA discontinuation in patients with HBeAg-negative CHB who were receiving NA 
therapy for at least five years and had no evidence of cirrhosis before NA initiation. 
The current study represents a group of patients with long-term (3 years) of follow-up 
after treatment discontinuation that were recruited from the outpatient clinic of the 2nd 
Academic Department of Internal Medicine at “Hippocration” General Hospital of 
Athens, Greece.   
Twenty-three adult patients under maintenance therapy stopped NA treatment. The 
main inclusion criteria for participation in the discontinuation study were as follows: 
documented HBeAg negative chronic hepatitis B before NA therapy initiation, 
absence of cirrhosis defined by liver stiffness <10 kPa assessed by transient 
elastography (Echosens) or Ishak score <4 at liver biopsy; treatment with NA or a 
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combination of NAs for at least 5 years and undetectable serum HBV DNA for at 
least 4 years. Patients were excluded if they had: co-infection with hepatitis D virus 
(HDV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV); any 
additional cause for liver injury; history of liver decompensation, malignancy including 
hepatocellular carcinoma (HCC) or history of liver transplantation. The study was 
approved by an independent ethics committee of the Hippocration General Hospital 
and was conducted according with the principles of the Declaration of Helsinski. All 
patients signed an informed consent before screening for their participation. 
Nine untreated patients with HBeAg-negative chronic HBV infection (previously 
termed “inactive carriers”) served as controls for the present study. All of them were 
HBsAg positive, HBeAg negative / anti-HBe positive with ALT values <40 IU/l on at 
least 4 occasions for the last 12 months, serum HBV DNA levels <2,000 IU/mL and 
liver stiffness < 7 kPa at transient elastography. 
A second matched population of thirty-eight non-cirrhotic HBeAg-negative CHB 
patients under maintenance therapy without stopping NAs were recruited to assess 
the potential for using cut-off values of identified genes to stop treatment.   
 
 
Study Design - Definitions 
The study was divided into two parts. Firstly, an investigative study to identify 
determinants associated with off-treatment remission and secondly a cross-sectional 
analysis of patients on long-term treatment (Figure 1). This second part was 
conducted to investigate if determinants identified in the first part of the study could 
be used to subdivide patients on NA therapy into two discrete populations, one of 
which could be targeted for cessation of therapy.  
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PBMC samples for gene expression analysis were collected at the end of treatment 
(EOT) and at 6th months after NA discontinuation for three of the patients. All patients 
were followed-up for at least 36 months after stopping treatment. According to the 
protocol all patients had monthly visits during the first 3 months and every 2 to 3 
months thereafter. Clinical examination and liver function tests were performed at 
each visit. Serum HBV DNA levels were measured every 3 months for the first year 
and 6 monthly thereafter. Serum HBsAg quantification was performed at the EOT 
and every 6 months. The upper limit of normal (ULN) for ALT and AST was 40 IU/L 
and serum HBV DNA levels were assessed by a polymerase chain reaction assay 
with sensitivity of 13 IU/mL. 
In the present study the definition of remission was based on the combination of 
biochemical and virological profile; remission was defined as ALT < 40IU/l and serum 
HBV DNA levels < 20,000 IU/mL or ALT > 40IU/l in only one-measurement and 
serum HBV DNA levels < 20,000 IU/mL for at least 36 months after treatment 
cessation.  
 
Methods 
Isolation of PBMCs and mRNA purification  
Blood samples were collected from 23 patients who stopped NA treatment at the End 
Of Treatment (EOT) and 3 of the patients with off-treatment remission at 6th months 
post-therapy cessation. Blood samples were also collected from 38 patients on long-
term NA therapy and from 9 controls. PBMCs were isolated from 10-20 mls blood 
using Ficoll Histopaque 1077-1 (SIGMA, St Louis, MO, USA) density centrifugation. 
Cell pellets were lysed with TRIzol (Invitrogen, Life Technologies, Grand Island, NY, 
USA) and kept at -80 °C until mRNA extraction. mRNA was extracted and purified 
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using the RNeasy Mini kit (QIAGEN, CA, USA). A NanoDrop 1000 
Spectrophotometer (Thermo Scientific, Wilmington, Delaware) was used to 
determine the quality and quantity of the mRNA. 
 
Agilent Whole Human Genome Oligo Microarrays  
Agilent Whole Human Genome Oligo Microarrays (Miltenyi Biotec, GmbH) were used 
to analyse PBMCs: taken at the EOT from 3 patients with off-treatment relapse; from 
3 patients with off-treatment remission taken at the EOT and at 6th months post-
treatment; and from 5 controls. Microarray image files were processed using Agilent 
Feature Extraction software (FES, Agilent Technologies, Inc). For determination of 
differential gene expression FES derived output data files were further analysed 
using the Rosetta Resolver® Gene expression data analysis system (Rosetta 
Inpharmatics LLC).  The signal intensities were normalized by dividing the intensity 
values by their median. The significance threshold was a nominal p-value p<0.05. 
Principal component analysis (PCA) was performed using the rgl package in R 17. 
Results were also displayed as a Heat map using MultiExperiment Viewer 18. To 
assess the relationship between the genes, Kyoto Encyclopaedia of Genes (KEGG) 
and Genomes pathway analysis (DAVID v6.7) 19 software were applied. 
 
Reverse transcription - qRT-PCR 
mRNA samples of 10 patients with off-treatment relapse (at the EOT), from 7 patients 
with off-treatment remission (at the EOT), from 4 controls and from 38 patients on NA 
therapy were used for qRT-PCR. cDNA was reverse transcribed using Applied 
Biosystems High Capacity cDNA Kit (USA). qPCR was performed using Taqman® 
Low Density Array System (Life Technologies, USA). The TaqMan array was 
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designed for custom configuration with 21 pre-dispensed primer assays for the target 
genes and 3 for the endogenous controls (Housekeeping genes: GAPDH, B2-
microglobulin and B-actin).  Relative levels of gene expression were calculated using 
ΔCt (threshold cycle) method. The GAPDH housekeeping gene was used to 
normalize the RNA amounts. Results are expressed relative to GAPDH using the 
equation: Relative quantity (Fold change): 2-ΔCt, where ΔCt = Ct target gene – Ct GAPDH 
 
Statistical Analysis 
Data was analysed using GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, 
CA) and SPSS (version 22; SPSS Inc, Chicago, IL).  Patient characteristics were 
compared using Mann-Whitney test for continuous variables and chi-square or 
Fisher’s exact tests for categorical variables. The Mann-Whitney test was used to 
compare gene expression levels between the clinical groups and Wilcoxon matched-
pairs signed rank test to compare gene expression levels between different time 
points of the same individuals. Receiver Operating Characteristic (ROC) curves for 
the accuracy of prediction of off-treatment remission or relapse were derived and 
thresholds of gene expression levels were calculated [with areas under the ROC 
curves (AUCROC) and their 95% confidence intervals (CI)]. Gene expression levels 
were log-transformed to achieve normality and to be included in the univariable 
logistic regression analysis. Multivariable logistic regression analysis was applied to 
the predictors, which were significant at the univariable analysis. Correlations were 
analysed using the Spearman’s rank test (rho). The level of p<0.05 was considered 
to be statistically significant. 
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RESULTS 
 
Population characteristics and outcome 
The main characteristics of the patients are shown in Table 1.  For the individuals 
that stopped NA therapy, the mean age was 59±9 years and 15 of the 23 patients 
were males. The median duration of NA treatment was 8 (5-14) years and the 
median off-treatment follow-up period 4.6 (3.2-5.2) years. Off-treatment remission 
was observed in 10 of the 23 patients (43%); Seven out of ten patients with remission 
achieved non-detectable serum HBV DNA levels at 30 (±20) months after treatment 
discontinuation. Two patients had ALT >40 Ul/mL in only one measurement during 
the follow-up.  
According to the study design, six of the 23 patients and 5 of the controls were used 
to perform whole genome gene expression analysis (“development cohort”). Three 
out of six patients relapsed after a mean of 2.6 (±0.6) months and three had off-
treatment remission with median serum HBV DNA levels 172 (0-9300) IU/ml, 2000 
(0-4000) IU/ml, 2470 (0-4410) IU/ml at 12, 24 and 36 months respectively. 
Seventeen of the 23 patients and four of the controls were studied as a “validation 
cohort” performing the qRT-PCR gene expression analysis. Ten of these had off-
treatment relapse after a mean of 5.2±4 months and seven had remission with 
median serum HBV DNA levels 3084 (0-9200) IU/ml, 170 (0-6650) IU/ml, 63 (0-
10907) IU/ml at 12, 24 and 36 months respectively. HBV DNA levels of the patients 
with off-treatment remission during the follow-up period are shown in Supplementary 
Table 1. No significant difference in baseline characteristics was observed between 
the development and validation groups (Table 1).  
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Patients with off-treatment remission have a distinct gene expression profile 
Micro array analysis was performed in “the development sub-cohort”: three patients 
with off-treatment relapse at the end of treatment (EOT); three patients with off-
treatment remission at the EOT and six months following cessation of therapy; and 
five controls.  This demonstrated that there were 1649 differentially expressed genes 
(p<0.05 after Bonferoni correction) between patients with off-treatment remission and 
relapse, 2231 differentially expressed genes between patients with off-treatment 
remission and controls, and 730 differentially expressed genes between patients with 
off-treatment remission at the EOT and at 6 months post-treatment. One hundred 
and sixty differentially expressed genes had a greater than two-fold increase and 201 
a greater than two-fold decrease between patients with off-treatment remission and 
relapse. Unsupervised hierarchical clustering analysis of the oligo-microarray data 
suggested that the three patients with off-treatment remission at the EOT clustered 
as a distinct group compared to the other groups (relapsers, controls and patients 
with remission at 6 months after treatment cessation) (Figure 2A), which was also 
illustrated by the principal component analysis (PCA) (Figure 2B). 
The heat map, which was created using only the differentially expressed genes 
between patients with remission at the EOT and relapse, again demonstrated that 
the group with remission clustered as an out-group to the others (Figure 2C). The 
cytokine-cytokine receptor interaction pathway was the most significantly different in 
the off-treatment remission group compared to the other groups [p=3.14 x10-4, false 
discovery rate (FDR) 0.002] as determined by Kyoto Encyclopedia of Genes (KEGG) 
and Genomes pathway analysis (DAVID v6.7).  
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Comparison of expression levels for the target genes between patients with 
off-treatment remission and relapse.   
We selected 21 differentially expressed key genes based on the fold change 
difference between the patients with off-treatment remission and relapse, their 
participation in the cytokine-cytokine receptor interaction pathway and their potential 
immunological relevance for controlling HBV infection.  All had p values of less than 
0.05 after Bonferoni correction. The levels of expression for these 21 target genes 
were determined by qRT-PCR on the “validation sub-cohort”. The results indicated 
that 10 of the 21 genes were expressed at significantly lower levels in the patients 
with off-treatment remission as compared to the patients with relapse (Figure 3). 
Specifically, patients with remission had lower expression of CCL20 (14 fold 
decrease (fd), p=0.03), CCL4 (5.9 fd, p=0.02), CXCL2 (18 fd, p=0.02), CXCL3 (17.6 
fd, p=0.01), IFNγ (5.3 fd, p=0.01), IL-8 (5.7 fd, p=0.01), IL-1A (61 fd, p=0.03), IL-1B 
(8.6 fd, p=0.05), FASLG (2 fd, p=0.01) and TNFRSF9 (2.9 fd, p=0.05) 
(Supplementary Table 2). Additionally, ROC curve analysis of the 10 target genes 
showed that expression levels of the genes was a potentially useful marker for 
discriminating patients who will have off-treatment remission with AUROCs of 0.78-
0.92 (95% CI: 0.56-1.00, p <0.05) (Figure 4).  The best performing genes were CCL4 
(AUROC: 0.929), IFNγ and IL-8 (AUROC: 0.871), CXCL3 and FASLG (AUROC: 
0.857). 
 
Predictive model of the off-treatment remission or relapse 
Univariable logistic regression analysis of the expression of the 10 target genes 
indicated that low expression of the target genes was associated with off-treatment 
remission after NA therapy cessation (Table 2). Specifically, we observed significant 
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association for FASLG (p=0.030), IFNγ (p=0.032), IL-8 (p=0.048) after log-
transformation and a trend for the CCL4 (p=0.053). Multivariate logistic regression 
analysis revealed that none of the four genes associated with off-treatment remission 
on univariate analysis remained independently significant; a trend towards 
association with off-treatment remission was observed for IFNγ (p=0.073). 
 
Expression levels of the target genes and HBsAg clearance 
Four of the twenty-three patients (17.4%) who stopped NA therapy achieved HBsAg 
loss after a mean of 30 (±23) months. These patients had a mean age 71±4 years, 
ALT levels 20±3 IU/mL and liver stiffness 5.4±1 kPa.  The duration of NA treatment 
was 6±0.5 years, 3 were treated with TDF and one with ETV.  The duration of follow-
up for them was 54±12 months and at EOT all patients had HBsAg <1000 IU/mL with 
two having levels <100 IU/mL. These four patients had significantly lower expression 
levels of FASLG (p=0.04), IL-8 (p=0.02), CCL4 (p=0.008) and a trend for IFNγ 
(p=0.06), compared to those who did not achieve seroclearance during follow-up.  
 
Stratifying patients on NA treatment using levels of immune response genes 
Expression of CCL4, IFNγ, IL-8 and FASLG, the four genes that were significantly 
associated with off treatment remission in the logistic regression analysis, was 
determined by qRT-PCR in the 38 patients on long-term NA therapy to determine if a 
discrete sub-group of individuals could be identified with a similar immune signature 
to the sustained responders. These individuals could then be potential candidates for 
stopping treatment.  We used ROC curve analyses of the validation sub-cohort to 
derive the cut-off values in gene expression levels, which discriminate patients into 
two sub-groups. Patients with gene expression levels lower than the cut-off values 
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will have potential off treatment remission and higher potential relapse. We applied 
these cut-off values on the gene expression levels of the 38 on treatment patients. 
Patients with CCL4 expression levels lower than 0.098, IFNγ expression levels lower 
than 0.0057, IL-8 expression levels lower than 0.12 or FASLG expression levels 
lower than 0.0038 could be potential sustained responders with a sensitivity of 
prediction 71.4-85.7% and specificity 80-90% (Figure 5A). Twelve (31.6%) of the 38 
patients had expression levels lower than the cut-off values for all four genes and 
therefore could be considered for stopping treatment (Figure 5B).  
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DISCUSSION 
NAs are widely used by the majority of the physicians in the treatment of patients 
with CHB and they have been proved very effective and safe 4, 5. Long term 
maintenance therapy with NAs is associated with sustained viral suppression and an 
improvement in histology and overall outcomes 6-8.  However, it does not affect 
serum HBsAg levels and HBsAg loss rarely is achieved particularly in HBeAg 
negative patients 20, 21. Recently, a number of small studies have shown that NA 
therapy can be stopped in patients with HBeAg negative CHB who have long-term 
viral suppression and the evaluation of NA treatment withdrawal has shown higher 
HBsAg loss rates than in studies with long-term NA. This has resulted in inclusion of 
possible treatment withdrawal as an option in recent European guidelines for the 
treatment of HBV infection, based on the duration of HBV DNA negativity 5. The host 
immune response plays a crucial role in HBV clearance and is expected to 
participate in the maintenance of an off-treatment remission 22-24. This is the first 
study investigating PBMC RNA levels as an accessible indicator of immune activity in 
patients with HBeAg negative CHB who stopped long term NA therapy. Our results 
have shown that low gene expression of CCL4, IFNγ, IL-8 and FASLG is associated 
with off treatment remission.  
Our study was based on prospectively collected data from a clinical multicenter 
cohort of HBeAg negative non-cirrhotic patients. We used two different cohorts. In 
the development cohort we analyzed PBMCs using the whole genome microarray 
methodology. We found that patients with off-treatment remission had a distinct 
immunological pattern, which was confirmed when we performed qRT-PCR in the 
validation cohort. Ten out of 21 genes were significantly down regulated in the 
patients with off-treatment remission as compared to the patients who relapsed 
		
18	
during the follow up.  These genes belong to the cytokine-cytokine receptor 
interaction pathway, are pleiotropic and secreted by both adaptive and innate 
immune cells. Using robust statistical analysis with the areas under the curve (AUC) 
and logistic regression we found that four genes (IFNγ, IL-8, FASLG and CCL4) 
could serve as predictive factors for off-treatment remission with AUC: 0.78-0.92 
(95% confidence interval (CI) 0.56 to 1, p <0.05). None of these factors are 
independently associated with off-treatment remission, which is not surprising as the 
immune system is complex with multiple interactions and individual immune 
components do not function in isolation. The same four genes, which predict off-
treatment remission, are down regulated in the patients with successful 
seroclearance during the follow-up supporting again the immunological potency for 
sustained HBV suppression after NA discontinuation.  
We hypothesized that gene expression patterns within the PBMC would indicate if 
there was a beneficial immune status that was predictive of remission. Overall this 
appear to show that lower levels of markers associated with immune cell activation 
were found in the patients with off-treatment remission, suggesting that their immune 
system had been “turned down”. Patients with off-treatment remission had a distinct 
immunological pattern at the EOT compared to 6 months post-treatment probably 
due to a subsequent increase in viral load with an associated immune response.  
One hypothesis is that the turning down of the immune system may subsequently 
result in “re-priming” of the immune system if the virus rebounds, and resulting in 
better subsequent viral control, as observed by Höner zu Siederdissen et al, who 
correlated rebound in HBV DNA with subsequent HBsAg loss 25. Further longitudinal 
studies would help to ascertain if these individuals relapse in the long run and if this 
is associated with an up-regulation of these immune markers. IFNγ is a well-known 
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effector cytokine, an immune marker, which can “turn on” the cellular antiviral 
mechanism by inducing the expression of several antiviral proteins modulating both 
innate and adaptive immune responses 26, 27. FasL and IL-8 have both been 
previously associated with active CHB.  In particular, the HBx protein can 
transactivate the FasL 28, 29 and the IL-8 promoters 30, thereby up regulating the 
expression of these genes. Also, HBV-specific T cells can produce IL-8 during active 
CHB, and flares of liver inflammation (either spontaneous or induced by anti-viral 
withdrawal) have been shown to be preceded by a parallel increase of IL-8 
production and serum HBV DNA levels 31-34. Specific inhibition of IL-8 increased the 
potency of IFNα against HBV in vitro and the addition of recombinant human IL-8 
almost totally rescued HBV replication during IFN challenge, strongly suggesting that 
IL-8 expression induced by HBV can impair the ability of endogenous IFNα to inhibit 
early stages of viral replication, thus favoring viral persistence 35. Inhibition of IL-8 
activity could be instrumental to the suppression of viral activity and to the 
improvement of IFNα antiviral action.  
Previous work from Rivino et al 36 and Rinker et al 37 have analysed T cell responses 
following cessation of NA therapy.  Both studies used in vitro stimulation of T cells 
with HBV peptides in order to specifically amplify low frequency T cell responses, 
with contrasting results.  In the study of Rivino et al, expression of PD-1 was 
associated with beneficial responses as defined by an absence of a flare in ALT, 
whereas Rinker et al described an absence of PD-1 on T cells as being beneficial in 
terms of HBsAg loss.  These data are consistent with discrete mechanisms operating 
in these two different scenarios.  For prolonged viral suppression, the presence of 
PD-1 positive T cells, which may represent T cell memory populations with improved 
survival characteristics 38, appears important.  Whereas following a virological 
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relapse T cell priming may be required, in which case PD-1 negative T cells may be 
more important.  Our data studies patients with a response pattern similar to the work 
of Rivino, in which memory responses may be present and so lower levels of T cell 
help are required to maintain immune response, and control of viral replication. Thus 
the immune response appears to be turned down.  Furthermore, low frequency T cell 
responses, which require antigen specific stimulation in vitro in order to become 
detectable, are unlikely to be identified using our unbiased approach. 
The percentage of our patients with off-treatment remission and HBsAg loss is in 
accordance with the results of other clinical studies 9, 10, 13, 39-41. Although several 
studies tried to explore the factors that may predict the post-cessation outcome, none 
revealed a strong or reliable indicator 10, 13, 25, 39, 42, 43. The significance of serum 
HBsAg levels at the time of discontinuation as an indicator of remission has been 
debatable with contradictory results among the studies 13, 41, 44-48 while novel HBV 
markers, such as core-related antigen (HBcrAg) 49, 50 and HBV RNA 51, 52 need to be 
assessed in larger cohorts prospectively. The data regarding the course of patients 
before losing HBsAg after NA discontinuation are conflicting 11. Interstingly, Höner zu 
Siederdissen et al 25 reported that patients with HBsAg loss had significant increases 
in serum HBV DNA after treatment discontinuation.  These authors also reported the 
presence of antigen-specific PD-1 negative T cells correlating with this 37. As noted 
above this population appears to be immunologically distinct from individuals who 
have prolonged viral suppression.  However given the conflicting results in this area, 
we consider that an approach which predicts prolonged viral suppression would 
currently be more clinically applicable, than one which relies on a later association 
with HBsAg loss.  Further studies in this area will be important both in identifiying 
additional markers, but also in determining which short term outcomes are best 
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predictive of long term benefit.  
The study has some limitations. Applying immunological predictive factors in clinical 
practice is more cumbersome than serological analysis, however given current 
technological advances and the advent of personalized medicine, costs are likely to 
fall. Additionally, further investigation is needed to define the thresholds of gene 
expression levels giving the highest AUC, which may predict the off-treatment 
remission. The small number of patients who stopped NA treatment is another 
drawback but the risk of post-treatment relapse and the need for close follow-up after 
treatment cessation made the identification of these patients challenging. Thirdly, we 
included non-cirrhotics, Caucasians with HBV genotype D infection patients and 
therefore our results may not be generalizable to all patients. Finally, it might be 
argued that off-treatment remission is a dynamic condition and remission or relapse 
rates may change during the follow up with the percentages of relapse varying 
considerably among studies 10. However, we should emphasize that we have 
prospectively collected data, we used strict criteria for remission and all patients have 
been followed for 36 months, which strengthen our data.    
In conclusion, our results demonstrated that the HBeAg-negative CHB patients on 
effective long-term therapy with NAs who stopped NA treatment and had off-
treatment remission seem to share a distinct immune profile from those patients with 
an off-treatment relapse. Expression levels of the CCL4, IL-8, IFNγ and FASLG 
genes could be used as potential biomarkers of off-treatment remission and could 
stratify those patients on NA treatment for consideration of treatment cessation. Our 
data showed for first time the predictive significance of immunological biomarkers in 
patients with HBeAg-negative CHB who stopped NAs and underlined the need for 
further research with a higher number of patients confirming our results. 
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TABLES 
 
Table 1: Baseline characteristics of the chronic hepatitis B (CHB) patients and 
inactive carriers (controls). No significant differences were observed between the 
patients or controls  
 
Baseline 
characteristics 
Development cohort  
(N=11) 
Validation cohort 
(N=21) 
 
Cross-
sectional 
cohort 
 CHB Patients Inactive 
carriers 
(Controls) 
CHB 
Patients 
Inactive 
carriers 
(Controls) 
CHB 
Patients 
Number (N) 6 5 17 4 38 
Gender (M/F) 3/3 2/2 12/5 2/3 26/12 
Age (years)† 57±8.4 44±19 59.8±11 37.5±10.4 53.9±12 
ALT (IU/ml)† 23.2±5.6 23±3.4 22.4±6.2 21±5.4 22±7.6 
HBV DNA 
(IU/ml)† 
Undetectable 864±1019 Undetectable 1091±425 Undetectable  
HBsAg  
(log10 IU/ml)† 
3.4±3.4 N/A 3±3.1 N/A N/A 
Duration of NA 
treatment 
(years)‡ 
8 (6-14) 0 8 (5-13) 0 8 (5-13) 
Duration of 
follow-up 
(months)‡ 
65 (61-68) - 61 (38-68) - - 
 
(†Mean ± SD, ‡Median (range), NA: Nucleos(t)ide Analogue, N/A: Not available) 
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Table 2: Univariable logistic regression analysis of the expression of the 10 target 
genes with the off-treatment remission and relapse. 
 
Variables  B S.E P value Odds 
Ratio 
95% CI of OR 
Lower Upper 
 Lower  Upper  
CCL20 0.653 0.344 0.057 1.922 0.980 3.769 
CCL4* 3.317 1.911 0.053 27.568 0.652 1165.958 
CXCL2 0.954 0.535 0.074 2.596 0.910 7.401 
CXCL3 1.257 0.663 0.058 3.514 0.958 12.894 
FASLG* 3.394 1.568 0.030 29.783 1.379 643.079 
IFNγ* 1.242 0.580 0.032 3.463 1.112 10.788 
IL-1A 0.618 0.332 0.063 1.855 0.968 3.555 
IL-1B 0.858 0.484 0.076 2.358 0.914 6.083 
IL-8* 1.090 0.550 0.048 2.973 1.012 8.737 
TNFSF9 1.188 0.625 0.057 3.280 0.963 11.166 
*P ≤ 0.05 
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FIGURE LEGENDS 
 
Figure 1: Flow-chart diagram illustrating study design 
Patients: Non-cirrhotic HBeAg-negative Chronic Hepatitis B (CHB) patients on long-
term treatment with Nucleos(t)ides analogues (NAs); Sub-cohorts: Patients who 
stopped NA therapy (Development and Validation cohort) and had at least 36 months 
of follow-up (n=23); Patients on NAs without cessation of therapy (Cross-sectional 
cohort, n=38); Controls (C): Nine untreated patients with HBeAg-negative chronic 
HBV infection (previously termed “inactive carriers”); Off-treatment remission was 
defined as ALT < 40IU/l and serum HBV DNA levels < 20,000 IU/mL or ALT > 40IU/l 
in only one-measurement and serum HBV DNA levels < 20,000 IU/mL for at least 36 
months after treatment cessation   
Figure 2:  
(2A) Hierarchical clustering analysis for all the genes from the microarray analsyis 
showing that patients with off-treatment remission (REM-EOT) cluster as an out-
group; (2B) Principal component analysis for all the genes. (2C) Heat Map 
representing the microarrays comparing the differentially expressed genes between 
patients with off-treatment remission and relapse at the end of treatment (EOT). 
Genes which are relatively up-regulated are coloured red and those down–regulated 
are coloured green.  REL-EOT (N=3): patients with off-treatment relapse (End Of 
Treatment), REM-EOT (N=3): patients with off-treatment remission (End Of 
Treatment), REM-6 months (N=3): patients with off-treatment remission (6th months 
off-treatment for the same patients as REM-EOT), Control (N=5): untreated inactive 
carriers  
Figure 3: Relative mRNA expression of the 10 target genes, which are significantly 
differentially expressed between the patients with off-treatment remission (REM-
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EOT, n=7), relapse off-treatment (REL-EOT, n=10) and untreated carriers with 
inactive disease (n=4). mRNA was quantified by qRT-PCR, expression levels 
normalised to glyceraldehyde phosphate dehydrogenase (GAPDH) and the result 
expressed as fold expression. Shown are the mean ± SD expression levels. *p <0.05, 
**p ≤0.01 
Figure 4: Receiver Operator Characteristic (ROC) for prediction of off-treatment 
relapse using the expression levels of the 10 significantly differentially expressed 
genes. The Areas Under the ROC Curve (AUC) are shown. 
Figure 5: (5A) CCL4, IFNγ, IL-8 and FASLG expression levels of the patients on 
treatment (n=38). The cut-off values as determined by the ROC analyses were sued 
to divide the population into two subgroups, one with potential off-treatment 
remission (potential REM) and one with potential off-treatment relapse (potential 
REL). Bars represent mean ± SD. **** p-value < 0.0001. (5B) The percentage of 
patients on treatment with one, two, three or four genes below the cut off values. 
 
